P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy

      There has been minimal advancement in clinical treatments for anorexia nervosa (AN) over the past several decades. Considerable evidence suggests that altered brain serotonin (5-HT) function contributes to dysregulation of appetite, mood, motivation, and impulse control in AN. Psilocybin is a psychedelic whose mechanism of action is mediated by serotonin 2A (5-HT2A) receptor agonism, supporting the possibility that this drug might reverse AN symptoms.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect